Exelixis (EXEL) Set to Announce Quarterly Earnings on Tuesday

Exelixis (NASDAQ:EXEL) will be issuing its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.29 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The company had revenue of $479.65 million for the quarter, compared to analyst estimates of $481.23 million. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Trading Up 1.6 %

EXEL opened at $22.87 on Tuesday. Exelixis has a 12 month low of $18.08 and a 12 month high of $24.34. The company has a market cap of $6.74 billion, a PE ratio of 35.73, a price-to-earnings-growth ratio of 0.60 and a beta of 0.54. The company has a 50 day moving average of $22.55 and a 200 day moving average of $22.14.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 47,020 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the transaction, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at approximately $8,255,375.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Exelixis news, Director David Edward Johnson bought 190,000 shares of Exelixis stock in a transaction that occurred on Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares in the company, valued at $22,785,111. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares of the company’s stock, valued at $8,255,375.70. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on EXEL. JMP Securities reaffirmed a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a report on Wednesday, April 10th. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Friday, January 26th. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a report on Thursday, April 11th. Stifel Nicolaus increased their price target on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Finally, Royal Bank of Canada raised their price objective on shares of Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.